Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Non-Cystic Fibrosis Bronchiectasis Market Expected to Grow Between 2025 And 2029?
The market size of non-cystic fibrosis bronchiectasis has seen considerable growth in the past few years. The market is expected to expand from $3.5 billion in 2024 to $3.7 billion in 2025, with a compound annual growth rate (CAGR) of 5.8%. The notable growth during the historical period can be explained through factors such as increased incidence and prevalence, technological advancements in diagnosis, an aging population, governmental assistance and funding, enhancement in healthcare facilities, heightened awareness of diagnosis, a growing elderly population and environment exposure.
Predictions suggest a robust expansion for the non-cystic fibrosis bronchiectasis market in the coming years, with projected growth to reach $4.68 billion by 2029 at a CAGR of 6.1%. Several factors contribute to this promising outlook for the forecast period, including advancements in personalized healthcare, the discovery of fresh biomarkers, an escalation in funds for respiratory medicine, and increasing research and development efforts. Moreover, public health campaigns, the worldwide ageing demographic and the advancement of focused treatments are also pivotal contributors to this growth. The forecast period is marked by major trends such as digital health solutions, an emphasis on specialized treatments, the incorporation of artificial intelligence and machine learning, a transition towards home healthcare, patient-oriented strategies, and the rise of mobile health (mHealth) solutions.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17209&type=smp
What Are the Core Market Drivers Propelling Growth in the Non-Cystic Fibrosis Bronchiectasis Industry?
The escalating incidence of ailments affecting the respiratory system is projected to stimulate the expansion of the non-cystic fibrosis bronchiectasis market. Diseases related to the lungs and respiratory system, which can disrupt breathing and overall respiratory function, are on the rise. The escalating incidence of these diseases is mainly caused by amplifying environmental pollution, covering outdoor pollutants and internal irritants like tobacco smoke. The escalating incidence of respiratory infections provides the chance to enhance knowledge, diagnosis, and management of non-cystic fibrosis bronchiectasis through precise interventions and public health endeavors. For example, during the 2022-2023 season from week 37 to week 46, a UK governmental body, the Office for Health Improvement and Disparities reported 4,622 notifications of scarlet fever Group A Streptococcus bacteria, with 851 notifications occurring in week 46 alone. This is a marked increase from an average of 1,294 notifications (ranging from 258 to 2,008) over the same period over the past five years. Consequently, the escalating incidence of diseases affecting the respiratory system will stimulate the growth of the non-cystic fibrosis bronchiectasis market.
How Is the Non-Cystic Fibrosis Bronchiectasis Market Segmented?
The non-cystic fibrosis bronchiectasismarket covered in this report is segmented –
1) By Diagnosis: Computed Tomography (CT) Scan; Bronchoscopy; Chest X Ray; Lung Function; Sputum Culture Test; Blood Tests; Other Diagnosis Types
2) By Treatment: Surgery; Physiotherapy; Vaccination; Airway Pharmacotherapy; Antibiotics; Other Treatments
3) By End Use: Hospitals And Clinics; Ambulatory Care Centers; Other End Uses
Subsegments:
1) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT); Standard CT
2) By Bronchoscopy: Flexible Bronchoscopy; Rigid Bronchoscopy
3) By Chest X-Ray: Standard Chest X-Ray; Digital Chest X-Ray
4) By Lung Function: Spirometry; Peak Flow Measurement
5) By Sputum Culture Test: Bacterial Culture; Fungal Culture; Viral Culture
6) By Blood Tests: Complete Blood Count (CBC); C-Reactive Protein (CRP); Immunoglobulin Levels
7) By Other Diagnosis Types: Sweat Test; Genetic Testing; Exhaled Nitric Oxide Test
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=17209&type=smp
Which Regions Are Driving the Next Phase of the Non-Cystic Fibrosis Bronchiectasis Market Growth?
North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2024. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Market Trends and Innovations Are Shaping the Future of the Non-Cystic Fibrosis Bronchiectasis Industry?
Primary businesses in the non-cystic fibrosis bronchiectasis market are paying close attention to personalized treatment strategies such as nebulization solutions to increase the effectiveness of drug delivery and to encourage patient adherence. Nebulization solutions utilize cutting-edge technology for the precise and efficient distribution of respiratory drugs, thereby improving patient adherence and treatment results. For example, Zambon S.P.A, a pharmaceutical company based in Italy, was awarded a US FDA designation in April 2022 for their CMS I-neb therapy for patients suffering from non-cystic fibrosis bronchiectasis (NCFB). CMS I-net is a new treatment under investigation, positioned as potentially the first inhaled treatment of its class for adult NCFB patient who have been colonized with P. aeruginosa. NCFB is a persistent, progressive, and incurable respiratory illness. The breakthrough designation for CMS I-neb in the NCFB market signifies an approval of the registration process and potentially accelerates its development and review.
View the full report here:
How Is the Non-Cystic Fibrosis Bronchiectasis Market Defined and What Are Its Core Parameters?
Non-cystic fibrosis bronchiectasis is a chronic condition characterized by permanent and abnormal widening of the airways (bronchi) in the lungs. This results from repeated inflammation and infection, leading to damage and weakening of the bronchial walls. It can cause mucus buildup, persistent coughing, breathlessness, and recurrent respiratory infections. Treatment often involves managing symptoms, preventing exacerbations, and addressing underlying causes such as bacterial infections or immune system dysfunction.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17209
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model